Samjin Pharmaceuticals Statistics

Total Valuation

Samjin Pharmaceuticals has a market cap or net worth of KRW 222.92 billion.

Market Cap	222.92B
Enterprise Value	n/a

Important Dates

The next estimated earnings date is Tuesday, November 19, 2024.

Earnings Date	Nov 19, 2024
Ex-Dividend Date	n/a

Share Statistics

Samjin Pharmaceuticals has 12.77 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	12.77M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.28%
Owned by Insiders (%)	37.38%
Owned by Institutions (%)	1.27%
Float	5.61M

Valuation Ratios

The trailing PE ratio is 10.10.

PE Ratio	10.10
Forward PE	n/a
PS Ratio	0.81
PB Ratio	0.84
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.32.

Current Ratio	1.64
Quick Ratio	0.79
Debt / Equity	0.32
Debt / EBITDA	2.65
Debt / FCF	-4.85
Interest Coverage	13.15

Financial Efficiency

Return on equity (ROE) is 8.59% and return on invested capital (ROIC) is 4.44%.

Return on Equity (ROE)	8.59%
Return on Assets (ROA)	3.92%
Return on Capital (ROIC)	4.44%
Revenue Per Employee	467.63M
Profits Per Employee	37.36M
Employee Count	586
Asset Turnover	0.74
Inventory Turnover	2.26

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.82% in the last 52 weeks. The beta is 0.27, so Samjin Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	-23.82%
50-Day Moving Average	18,277.20
200-Day Moving Average	19,471.95
Relative Strength Index (RSI)	37.70
Average Volume (20 Days)	31,101

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Samjin Pharmaceuticals had revenue of KRW 274.03 billion and earned 21.89 billion in profits. Earnings per share was 1,727.82.

Revenue	274.03B
Gross Profit	117.73B
Operating Income	23.18B
Pretax Income	25.23B
Net Income	21.89B
EBITDA	33.00B
EBIT	23.18B
Earnings Per Share (EPS)	1,727.82

Full Income Statement

Balance Sheet

The company has 4.66 billion in cash and 87.51 billion in debt, giving a net cash position of -82.85 billion or -6,485.31 per share.

Cash & Cash Equivalents	4.66B
Total Debt	87.51B
Net Cash	-82.85B
Net Cash Per Share	-6,485.31
Equity (Book Value)	275.86B
Book Value Per Share	20,810.66
Working Capital	52.62B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 17.29 billion and capital expenditures -35.35 billion, giving a free cash flow of -18.06 billion.

Operating Cash Flow	17.29B
Capital Expenditures	-35.35B
Free Cash Flow	-18.06B
FCF Per Share	-1,413.77

Full Cash Flow Statement

Margins

Gross margin is 42.96%, with operating and profit margins of 8.46% and 7.99%.

Gross Margin	42.96%
Operating Margin	8.46%
Pretax Margin	9.21%
Profit Margin	7.99%
EBITDA Margin	12.04%
EBIT Margin	8.46%
FCF Margin	-6.59%

Dividends & Yields

This stock pays an annual dividend of 800.00, which amounts to a dividend yield of 4.72%.

Dividend Per Share	800.00
Dividend Yield	4.72%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	44.95%
Buyback Yield	2.00%
Shareholder Yield	6.72%
Earnings Yield	9.90%
FCF Yield	-8.10%

Dividend Details

Stock Splits

The last stock split was on December 29, 2010. It was a forward split with a ratio of 1.0312096.

Last Split Date	Dec 29, 2010
Split Type	Forward
Split Ratio	1.0312096

Scores

Samjin Pharmaceuticals has an Altman Z-Score of 3.25.

Altman Z-Score	3.25
Piotroski F-Score	n/a